Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback